News | January 29, 2024
Jubilant Pharmova Singapore to sell its entire 25.8% stake in Sofie Biosciences, USA
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
he US FDA has issued six observations pursuant to the completion of the audit.
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
Subscribe To Our Newsletter & Stay Updated
